Sofgen Pharma SA

Sofgen Pharma operates with a negative equity position of -$51.14 million and a debt-to-equity ratio of -6.0, indicating a highly leveraged capital structure with liabilities exceeding assets. Despite a negative net income of -$68.3 million, the company generated $88.43 million in operating cash flow, suggesting operational cash generation is robust relative to profitability. However, free cash flow was -$73.27 million, driven by capital expenditures of -$25.01 million, indicating reinvestment in operations or expansion. Profitability metrics show a return on assets (ROA) of -16.59%, reflecting underperformance relative to asset base, while return on equity (ROE) of 1.34% is marginally positive but weak given the negative equity position. Gross profit of $191.48 million on $373.79 million in revenue yields a 51.2% gross margin, which is strong for a pharmaceutical firm but insufficient to offset operating and net losses. The company operates through five segments: Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Revenue concentration is not disclosed, but the Diabetrics and Clinical Specialties units are likely the largest contributors, given their focus on prescription drugs and complex formulations. Geographically, the firm markets in Latin America through Diabetrics, but no other regions are specified in the financial snapshot. Outlook for the current fiscal year shows a revenue of $373.79 million, with a recent actual revenue of $423.75 million reported in analyst estimates, suggesting a potential decline in the near term. The company’s operating cash flow remains positive, but net income and free cash flow are negative, indicating ongoing profitability challenges despite cash generation. Risk factors include a medium liquidity risk, as the current ratio is 0.52, and the firm has a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. Recent events include a reported EPS of $0.40, which contrasts with the net loss of -$68.3 million, suggesting a discrepancy in earnings per share calculations or non-cash adjustments. No recent filings or transcripts are provided in the input data to further clarify operational developments.